Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Gyre Therapeutics's total assets was $201.25M at Sep 30, 2026. For fiscal 2025 it was $219.76M, up 75.2% from the year before. Over ten years it grew 12.2% a year on average. The highest annual figure on record is $262.79M in fiscal 2010.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.76M | +75.2% |
| FY2024 | Dec 31, 2024 | $125.41M | +7.6% |
| FY2023 | Dec 31, 2023 | $116.54M | +37.5% |
| FY2022 | Dec 31, 2022 | $84.75M | +52.3% |
| FY2021 | Dec 31, 2021 | $55.66M | -41.3% |
| FY2020 | Dec 31, 2020 | $94.85M | -3.8% |
| FY2019 | Dec 31, 2019 | $98.55M | -21.1% |
| FY2018 | Dec 31, 2018 | $124.92M | +216.1% |
| FY2017 | Dec 31, 2017 | $39.51M | +3.7% |
| FY2016 | Dec 31, 2016 | $38.09M | -45.2% |
| FY2015 | Dec 31, 2015 | $69.52M | +2232.1% |
| FY2014 | Dec 31, 2014 | $2.98M | -98.0% |
| FY2013 | Dec 31, 2013 | $145.87M | -23.1% |
| FY2012 | Dec 31, 2012 | $189.58M | -26.6% |
| FY2011 | Dec 31, 2011 | $258.13M | -1.8% |
| FY2010 | Dec 31, 2010 | $262.79M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $201.25M | +26.3% |
| Q2 FY2026 | Jun 30, 2026 | $199.26M | +30.5% |
| Q1 FY2026 | Mar 31, 2026 | $162.02M | +24.8% |
| Q4 FY2025 | Dec 31, 2025 | $219.76M | +75.2% |
| Q3 FY2025 | Sep 30, 2025 | $159.38M | +27.3% |
| Q2 FY2025 | Jun 30, 2025 | $152.65M | +26.2% |
| Q1 FY2025 | Mar 31, 2025 | $129.79M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | $125.41M | +7.6% |
| Q3 FY2024 | Sep 30, 2024 | $125.24M | +1156.9% |
| Q2 FY2024 | Jun 30, 2024 | $120.93M | +875.7% |
| Q1 FY2024 | Mar 31, 2024 | $122.01M | +550.7% |
| Q4 FY2023 | Dec 31, 2023 | $116.54M | +37.5% |
| Q3 FY2023 | Sep 30, 2023 | $9.96M | -67.9% |
| Q2 FY2023 | Jun 30, 2023 | $12.39M | -85.1% |
| Q1 FY2023 | Mar 31, 2023 | $18.75M | -53.4% |
| Q4 FY2022 | Dec 31, 2022 | $84.75M | +52.3% |
| Q3 FY2022 | Sep 30, 2022 | $31.02M | -60.5% |
| Q2 FY2022 | Jun 30, 2022 | $83.37M | -18.1% |
| Q1 FY2022 | Mar 31, 2022 | $40.27M | -66.2% |
| Q4 FY2021 | Dec 31, 2021 | $55.66M | -41.3% |
| Q3 FY2021 | Sep 30, 2021 | $78.54M | -29.8% |
| Q2 FY2021 | Jun 30, 2021 | $101.79M | -17.7% |
| Q1 FY2021 | Mar 31, 2021 | $119.08M | +7.7% |
| Q4 FY2020 | Dec 31, 2020 | $94.85M | -3.8% |
| Q3 FY2020 | Sep 30, 2020 | $111.80M | +21.8% |
| Q2 FY2020 | Jun 30, 2020 | $123.68M | +22.6% |
| Q1 FY2020 | Mar 31, 2020 | $110.56M | -1.2% |
| Q4 FY2019 | Dec 31, 2019 | $98.55M | -21.1% |
| Q3 FY2019 | Sep 30, 2019 | $91.79M | -31.2% |
| Q2 FY2019 | Jun 30, 2019 | $100.87M | -27.7% |
| Q1 FY2019 | Mar 31, 2019 | $111.87M | -23.3% |
| Q4 FY2018 | Dec 31, 2018 | $124.92M | +216.1% |
| Q3 FY2018 | Sep 30, 2018 | $133.42M | +287.9% |
| Q2 FY2018 | Jun 30, 2018 | $139.54M | +252.1% |
| Q1 FY2018 | Mar 31, 2018 | $145.89M | +402.0% |
| Q4 FY2017 | Dec 31, 2017 | $39.51M | +3.7% |
| Q3 FY2017 | Sep 30, 2017 | $34.39M | – |
| Q2 FY2017 | Jun 30, 2017 | $39.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.09M | – |
See a number that looks wrong?